215 related articles for article (PubMed ID: 23064281)
21. Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells.
Maynadier M; Shi J; Vaillant O; Gary-Bobo M; Basile I; Gleizes M; Cathiard AM; Wah JL; Sheikh MS; Garcia M
Mol Cancer Res; 2012 Nov; 10(11):1473-81. PubMed ID: 22964432
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
23. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Sato A; Asano T; Ito K; Asano T
J Urol; 2012 Dec; 188(6):2410-8. PubMed ID: 23088964
[TBL] [Abstract][Full Text] [Related]
24. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
[TBL] [Abstract][Full Text] [Related]
25. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
Freudlsperger C; Thies A; Pfüller U; Schumacher U
Anticancer Res; 2007; 27(1A):207-13. PubMed ID: 17352234
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
27. [Adenovirus-delivered tissue inhibitor of metalloproteinases-3 transfection increases the sensitivity of cervical cancer cells to cisplatin].
Zhang Y; Lin C; Qian HL; Lang JH; Fu M; Zhang XY; Liang X; Duan H; Xiang Y
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):25-9. PubMed ID: 17575689
[TBL] [Abstract][Full Text] [Related]
28. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.
Koivusalo R; Krausz E; Ruotsalainen P; Helenius H; Hietanen S
Cancer Res; 2002 Dec; 62(24):7364-71. PubMed ID: 12499281
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
An J; Sun Y; Fisher M; Rettig MB
Leukemia; 2004 Oct; 18(10):1699-704. PubMed ID: 15343345
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Wang M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q
Leukemia; 2008 Jan; 22(1):179-85. PubMed ID: 17898787
[TBL] [Abstract][Full Text] [Related]
31. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Yerlikaya A; Erin N
Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells.
Rastogi N; Duggal S; Singh SK; Porwal K; Srivastava VK; Maurya R; Bhatt ML; Mishra DP
Oncotarget; 2015 Dec; 6(41):43310-25. PubMed ID: 26621832
[TBL] [Abstract][Full Text] [Related]
34. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
35. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
36. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Kamer S; Ren Q; Dicker AP
Arch Gynecol Obstet; 2009 Jan; 279(1):41-6. PubMed ID: 18461345
[TBL] [Abstract][Full Text] [Related]
37. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
[TBL] [Abstract][Full Text] [Related]
38. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
40. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]